136 related articles for article (PubMed ID: 16392310)
1. [Fast remission of acute kidney failure after rasburicase use in tumor lysis syndrome].
Viedma G; Borrego FJ; Pérez del Barrio P; de Santi C
Nefrologia; 2005; 25(5):572-3. PubMed ID: 16392310
[No Abstract] [Full Text] [Related]
2. Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Canet E; Cheminant M; Zafrani L; Thieblemont C; Galicier L; Lengline E; Schnell D; Reuter D; Darmon M; Schlemmer B; Azoulay E
Leuk Lymphoma; 2014 Oct; 55(10):2362-7. PubMed ID: 24325633
[TBL] [Abstract][Full Text] [Related]
3. Rasburicase for Tumor Lysis Syndrome.
Vishwanathan S; Arumugarajah A; Ortega LM; Bousamra A
Am J Ther; 2019; 26(1):e118-e121. PubMed ID: 27563802
[No Abstract] [Full Text] [Related]
4. [Acute renal failure in patients with tumor lysis syndrome].
Nabeshima K; Saito S; Suzuki Y
Nihon Rinsho; 2004 May; 62 Suppl 5():486-90. PubMed ID: 15197969
[No Abstract] [Full Text] [Related]
5. Rasburicase therapy in acute hyperuricemic renal dysfunction.
Ronco C; Bellomo R; Inguaggiato P; Bonello M; Bordoni V; Salvatori G; D'Intini V; Ratanarat R
Contrib Nephrol; 2004; 144():158-65. PubMed ID: 15264405
[No Abstract] [Full Text] [Related]
6. Acute kidney injury associated with tumor lysis syndrome: a paradigm shift.
El-Husseini A; Sabucedo A; Lamarche J; Courville C; Peguero A
Am J Emerg Med; 2012 Feb; 30(2):390.e3-6. PubMed ID: 21296524
[No Abstract] [Full Text] [Related]
7. Rasburicase (elitek) for hyperuricemia.
Med Lett Drugs Ther; 2002 Nov; 44(1143):96-7. PubMed ID: 12432325
[No Abstract] [Full Text] [Related]
8. Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist.
Patel V; Case R
J Investig Med High Impact Case Rep; 2020; 8():2324709620944709. PubMed ID: 32720820
[TBL] [Abstract][Full Text] [Related]
9. Rescue Therapies for AKI in Onconephrology: Rasburicase and Glucarpidase.
Latcha S; Shah CV
Semin Nephrol; 2022 Nov; 42(6):151342. PubMed ID: 37167817
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
[TBL] [Abstract][Full Text] [Related]
11. Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis.
Macfarlane RJ; McCully BJ; Fernandez CV
Pediatr Nephrol; 2004 Aug; 19(8):924-7. PubMed ID: 15179573
[TBL] [Abstract][Full Text] [Related]
12. [Rasburicase (Fasturtec)].
Vogt B; Gugger M; Frey FJ
Ther Umsch; 2004 Sep; 61(9):579-82. PubMed ID: 15493120
[TBL] [Abstract][Full Text] [Related]
13. Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome.
Cairo MS
Clin Lymphoma; 2003 Mar; 3(4):233-4. PubMed ID: 12672272
[No Abstract] [Full Text] [Related]
14. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
[TBL] [Abstract][Full Text] [Related]
15. Tumor lysis syndrome, case report and review of the literature.
Masera G; Jankovic M
Ann Oncol; 1997 Jan; 8(1):97. PubMed ID: 9093714
[No Abstract] [Full Text] [Related]
16. [Kidney protection--pain control--infection prevention. So that quality of life and cancer are not a contradiction].
Aumiller J
MMW Fortschr Med; 2004 Dec; 146(50):4-6. PubMed ID: 15658513
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
Pession A; Barbieri E; Santoro N; Paolucci P; Porta F; Locatelli F
Haematologica; 2005 Jan; 90(1):141-2. PubMed ID: 15642687
[TBL] [Abstract][Full Text] [Related]
18. [The pathophysiology, clinical signs and therapy of urate nephropathy].
Méhes L; Udvardy M; Szász R; Rejto L
Orv Hetil; 2007 Apr; 148(16):745-8. PubMed ID: 17437951
[TBL] [Abstract][Full Text] [Related]
19. [Acute renal failure in patients with tumour lysis sindrome].
Poskurica M; Petrović D; Poskurica M
Srp Arh Celok Lek; 2016; 144(3-4):232-9. PubMed ID: 27483573
[TBL] [Abstract][Full Text] [Related]
20. Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Hooman N; Otukesh H
Iran J Kidney Dis; 2011 Mar; 5(2):130-2. PubMed ID: 21368393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
